DAVID MOLITERNO, University of Kentucky, Lexington REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking Trials An oral thrombin receptor antagonist, SCH 530348 has proved saf
DAVID MOLITERNO, University of Kentucky, Lexington
REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking TrialsAn oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC’s New Orleans meeting byDavid Moliternowho discussed the new data with Peter Goodwin.
Related Episodes
LDL-How Low?
Terje Pedersen Terje Pedersen, Ulleval University, Oslo Eugene Braunwald, Harvard University, Boston Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no be
Bivalirudin For Angioplasty: Expensive Heparin?
Tony Gershlick Tony Gershlick, University of Leicester Adnan Kastrati, Deutsches Herzzentrum, Munich Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing deat
Remove Thrombus Before Primary Angioplasty!
Felix Zijlstra Felix Zijlstra, University Medical Center Groningen, The Netherlands Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits,